Embody Biosignals Limited 09742798 false 2022-09-01 2023-08-31 2023-08-31 The principal activity of the company is scientific research. Digita Accounts Production Advanced 6.30.9574.0 true 09742798 2022-09-01 2023-08-31 09742798 2023-08-31 09742798 bus:Original 2023-08-31 09742798 core:CurrentFinancialInstruments core:WithinOneYear 2023-08-31 09742798 bus:Micro-entities 2022-09-01 2023-08-31 09742798 bus:AuditExemptWithAccountantsReport 2022-09-01 2023-08-31 09742798 bus:FullAccounts 2022-09-01 2023-08-31 09742798 bus:SmallCompaniesRegimeForAccounts 2022-09-01 2023-08-31 09742798 bus:RegisteredOffice 2022-09-01 2023-08-31 09742798 bus:Director1 2022-09-01 2023-08-31 09742798 bus:PrivateLimitedCompanyLtd 2022-09-01 2023-08-31 09742798 countries:EnglandWales 2022-09-01 2023-08-31 09742798 2021-09-01 2022-08-31 09742798 2022-08-31 09742798 core:CurrentFinancialInstruments core:WithinOneYear 2022-08-31 iso4217:GBP xbrli:pure

Registration number: 09742798

Embody Biosignals Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 August 2023

 

Embody Biosignals Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

Embody Biosignals Limited

Company Information

Director

Professor C James

Registered office

Northgate House
North Gate
New Basford
Nottingham
NG7 7BQ

Accountants

RWB CA Limited
Northgate House
North Gate
New Basford
Nottingham
NG7 7BQ

 

Embody Biosignals Limited

(Registration number: 09742798)
Balance Sheet as at 31 August 2023

2023
£

2022
£

Current assets

3,732

2,555

Creditors: Amounts falling due within one year

(7,035)

(6,553)

Total assets less current liabilities

(3,303)

(3,998)

Accruals and deferred income

(194)

(170)

 

(3,497)

(4,168)

Capital and reserves

(3,497)

(4,168)

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Northgate House
North Gate
New Basford
Nottingham
NG7 7BQ

These financial statements were authorised for issue by the director on 19 February 2024.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

The financial statements have been prepared under the going concern basis.

2

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2022 - 1).

For the financial year ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

 

Embody Biosignals Limited

(Registration number: 09742798)
Balance Sheet as at 31 August 2023

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 19 February 2024
 

.........................................
Professor C James
Director